Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).

Kapoor R, Deek MP, McIntyre R, Raman N, Kummerlowe M, Chen I, Gaver M, Wang H, Denmeade S, Lotan T, Paller C, Markowski M, Carducci M, Eisenberger M, Beer TM, Song DY, DeWeese TL, Hearn JW, Greco S, DeVille C, Desai NB, Heath EI, Liauw S, Spratt DE, Hung AY, Antonarakis ES, Tran PT.

BMC Cancer. 2019 Jun 13;19(1):572. doi: 10.1186/s12885-019-5805-z.

PMID:
31196032
2.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Eur Urol. 2019 Apr 13. pii: S0302-2838(19)30208-8. doi: 10.1016/j.eururo.2019.03.022. [Epub ahead of print]

PMID:
30992160
3.

Moody D. Wharam Jr, MD, FACR, FASTRO, July 22, 1941-August 10, 2018.

Jabbour SK, Timmerman RD, Raben D, DeWeese TL, Donaldson SS, Thomas P, Laurie F, Bishop-Jodoin M, Tarbell N, Wolden S, Halperin E, Constine LS, Haas-Kogan D, Marcus K, Freeman C, Terezakis S, Million L, Smith MA, Mendenhall NP, Marcus RB Jr, Cherlow J, Kalapurakal J, Breneman J, Yock T, MacDonald S, Laack N, Donahue B, Indelicato D, Michalski J, Perkins S, Kachnic L, Esiashvilli N, Roberts KB, FitzGerald TJ.

Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1026-1030. doi: 10.1016/j.ijrobp.2019.01.004. Epub 2019 Mar 13. No abstract available.

PMID:
30900552
4.

Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities.

Marciscano AE, Haimovitz-Friedman A, Lee P, Tran PT, Tomé WA, Guha C, Spring Kong FM, Sahgal A, El Naqa I, Rimner A, Marks LB, Formenti SC, DeWeese TL.

Int J Radiat Oncol Biol Phys. 2019 Mar 2. pii: S0360-3016(19)30290-1. doi: 10.1016/j.ijrobp.2019.02.046. [Epub ahead of print] No abstract available.

PMID:
30836168
5.

Patterns of Incident Reporting Across Clinical Sites in a Regionally Expanding Academic Radiation Oncology Department.

Rhieu BH, Terezakis SA, Greco S, Deville C, Souranis AN, Choflet A, DeWeese TL, Viswanathan AN, Laub W, McNutt TR, Wright JL.

J Am Coll Radiol. 2019 Feb 7. pii: S1546-1440(18)31559-X. doi: 10.1016/j.jacr.2018.12.010. [Epub ahead of print]

PMID:
30738769
6.

Association of a Simulated Institutional Gender Equity Initiative With Gender-Based Disparities in Medical School Faculty Salaries and Promotions.

Rao AD, Nicholas SE, Kachniarz B, Hu C, Redmond KJ, Deville C, Wright JL, Page BR, Terezakis S, Viswanathan AN, DeWeese TL, Fivush BA, Alcorn SR.

JAMA Netw Open. 2018 Dec 7;1(8):e186054. doi: 10.1001/jamanetworkopen.2018.6054.

7.

Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.

Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W.

Urol Oncol. 2019 Apr;37(4):289.e19-289.e26. doi: 10.1016/j.urolonc.2018.09.016. Epub 2018 Nov 13.

PMID:
30446451
8.

Differences in Physician Compensation Between Men and Women at United States Public Academic Radiation Oncology Departments.

Guss ZD, Chen Q, Hu C, Guss LG, DeWeese TL, Terezakis SA.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):314-319. doi: 10.1016/j.ijrobp.2018.09.042. Epub 2018 Oct 10.

PMID:
30315874
9.

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.

Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.

Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30729-2. doi: 10.1016/j.eururo.2018.09.040. [Epub ahead of print]

PMID:
30293905
10.

Phase II study of intraoperative dosimetry for prostate brachytherapy using registered ultrasound and fluoroscopy.

Lee J, Hobbs RF, Zahurak M, Ng SK, Zhang Z, Burdette EC, DeWeese TL, Song DY.

Brachytherapy. 2018 Nov - Dec;17(6):858-865. doi: 10.1016/j.brachy.2018.07.013. Epub 2018 Sep 11.

PMID:
30217432
11.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.

World J Urol. 2018 Sep 6. doi: 10.1007/s00345-018-2477-2. [Epub ahead of print]

PMID:
30191396
12.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

PMID:
29976500
13.

Real-time management of incident learning reports in a radiation oncology department.

Wright JL, Parekh A, Rhieu BH, Opris V, Souranis A, Choflet A, Viswanathan AN, DeWeese TL, McNutt T, Terezakis SA.

Pract Radiat Oncol. 2018 Sep - Oct;8(5):e337-e345. doi: 10.1016/j.prro.2018.04.016. Epub 2018 May 8.

PMID:
29907503
14.

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.

Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, Mao W, Chaudhary KR, Chaimowitz MG, Wong J, Selby MJ, Thudium KB, Korman AJ, Ulmert D, Thorek DLJ, DeWeese TL, Drake CG.

Clin Cancer Res. 2018 Oct 15;24(20):5058-5071. doi: 10.1158/1078-0432.CCR-17-3427. Epub 2018 Jun 13.

PMID:
29898992
15.

Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.

Peng LC, Narang AK, Gergis C, Radwan NA, Han P, Marciscano AE, Robertson SP, He P, Trieu J, Ram AN, McNutt TR, Griffith E, DeWeese TA, Honig S, Singh H, Greco SC, Tran PT, Deville C, DeWeese TL, Song DY.

Urol Oncol. 2018 Jun;36(6):309.e7-309.e14. doi: 10.1016/j.urolonc.2018.02.008. Epub 2018 Mar 16.

PMID:
29551548
16.

Interventional Radiation Oncology (IRO): Transition of a magnetic resonance simulator to a brachytherapy suite.

Anderson R, Armour E, Beeckler C, Briner V, Choflet A, Cox A, Fader AN, Hannah MN, Hobbs R, Huang E, Kiely M, Lee J, Morcos M, McMillan PE, Miller D, Ng SK, Prasad R, Souranis A, Thomsen R, DeWeese TL, Viswanathan AN.

Brachytherapy. 2018 May - Jun;17(3):587-596. doi: 10.1016/j.brachy.2018.01.007. Epub 2018 Mar 13.

PMID:
29548553
17.

Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.

Hayman J, Phillips R, Chen D, Perin J, Narang AK, Trieu J, Radwan N, Greco S, Deville C Jr, McNutt T, Song DY, DeWeese TL, Tran PT.

Prostate. 2018 Jun;78(8):623-630. doi: 10.1002/pros.23507. Epub 2018 Mar 9.

PMID:
29520847
18.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.

Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR.

JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

19.

Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy.

Ferro A, Bae HJ, Yenokyan G, Le Y, McNutt T, Mian O, Gergis C, Haviland C, DeWeese TL, Song DY.

Brachytherapy. 2018 Mar - Apr;17(2):313-318. doi: 10.1016/j.brachy.2017.10.008. Epub 2017 Nov 23.

20.

Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy.

Bae HJ, Mian O, Vaidya D, DeWeese TL, Song DY.

Pract Radiat Oncol. 2018 May - Jun;8(3):e159-e165. doi: 10.1016/j.prro.2017.10.004. Epub 2017 Oct 10.

21.

Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers.

Rao AD, Coquia S, De Jong R, Gourin C, Page B, Latronico D, Dah S, Su L, Clarke S, Schultz J, Rosati LM, Fakhry C, Wong J, DeWeese TL, Quon H, Ding K, Kiess A.

Radiother Oncol. 2018 Jan;126(1):96-99. doi: 10.1016/j.radonc.2017.09.017. Epub 2017 Oct 3.

22.

A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer.

Rao AD, Feng Z, Shin EJ, He J, Waters KM, Coquia S, DeJong R, Rosati LM, Su L, Li D, Jackson J, Clark S, Schultz J, Hutchings D, Kim SH, Hruban RH, DeWeese TL, Wong J, Narang A, Herman JM, Ding K.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1111-1120. doi: 10.1016/j.ijrobp.2017.08.006. Epub 2017 Aug 14.

23.

A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).

Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, DeWeese TL, Dicker A, Eisenberger M, Tran PT.

BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.

24.

Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry.

Lee J, Mian OY, Le Y, Bae HJ, Burdette EC, DeWeese TL, Prince JL, Song DY.

Radiother Oncol. 2017 Jul;124(1):61-67. doi: 10.1016/j.radonc.2017.05.018. Epub 2017 Jun 21.

25.

TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis.

Malek R, Gajula RP, Williams RD, Nghiem B, Simons BW, Nugent K, Wang H, Taparra K, Lemtiri-Chlieh G, Yoon AR, True L, An SS, DeWeese TL, Ross AE, Schaeffer EM, Pienta KJ, Hurley PJ, Morrissey C, Tran PT.

Cancer Res. 2017 Jun 15;77(12):3181-3193. doi: 10.1158/0008-5472.CAN-16-2797. Epub 2017 May 8.

26.

End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.

Narang AK, Trieu J, Radwan N, Ram A, Robertson SP, He P, Gergis C, Griffith E, Singh H, DeWeese TA, Honig S, Annadanam A, Greco S, DeVille C, McNutt T, DeWeese TL, Song DY, Tran PT.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):203-209. doi: 10.1038/pcan.2016.67. Epub 2017 Jan 17.

27.

Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.

Tosoian JJ, Alam R, Gergis C, Narang A, Radwan N, Robertson S, McNutt T, Ross AE, Song DY, DeWeese TL, Tran PT, Walsh PC.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):193-196. doi: 10.1038/pcan.2016.64. Epub 2017 Jan 3.

28.

Identifying Predictive Factors for Incident Reports in Patients Receiving Radiation Therapy.

Elnahal SM, Blackford A, Smith K, Souranis AN, Briner V, McNutt TR, DeWeese TL, Wright JL, Terezakis SA.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):993-9. doi: 10.1016/j.ijrobp.2015.11.041. Epub 2015 Dec 14.

PMID:
27026305
29.

Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.

Narang AK, Gergis C, Robertson SP, He P, Ram AN, McNutt TR, Griffith E, DeWeese TA, Honig S, Singh H, Song DY, Tran PT, DeWeese TL.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):254-62. doi: 10.1016/j.ijrobp.2015.10.056. Epub 2015 Oct 31.

30.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL.

Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1.

31.

Bromopyridone Nucleotide Analogues, Anoxic Selective Radiosensitizing Agents That Are Incorporated in DNA by Polymerases.

Rudra A, Hou D, Zhang Y, Coulter J, Zhou H, DeWeese TL, Greenberg MM.

J Org Chem. 2015 Nov 6;80(21):10675-85. doi: 10.1021/acs.joc.5b01833. Epub 2015 Oct 28.

32.

A Roadmap for a New Academic Pathway for Global Radiation Oncology.

Olson AC, Coleman CN, Hahn SM, DeWeese TL, Shulman LN, Chabner BA, Chao N, Martei YM, Mundt AJ, Grover S.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):493-6. doi: 10.1016/j.ijrobp.2015.06.023. No abstract available.

PMID:
26460990
33.

GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress.

Mian OY, Khattab MH, Hedayati M, Coulter J, Abubaker-Sharif B, Schwaninger JM, Veeraswamy RK, Brooks JD, Hopkins L, Shinohara DB, Cornblatt B, Nelson WG, Yegnasubramanian S, DeWeese TL.

Prostate. 2016 Feb;76(2):199-206. doi: 10.1002/pros.23111. Epub 2015 Oct 8.

34.

Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.

Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWeese TL, Lupold SE.

Mol Cancer Ther. 2015 Dec;14(12):2797-804. doi: 10.1158/1535-7163.MCT-15-0291-T. Epub 2015 Oct 5.

35.

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.

Sharabi AB, Lim M, DeWeese TL, Drake CG.

Lancet Oncol. 2015 Oct;16(13):e498-509. doi: 10.1016/S1470-2045(15)00007-8. Review.

PMID:
26433823
36.

Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.

Sharabi AB, Tran PT, Lim M, Drake CG, Deweese TL.

Oncology (Williston Park). 2015 May;29(5):331-40. Review.

37.

A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation.

Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, Lupold SE.

Nucleic Acids Res. 2015 Apr 30;43(8):4075-86. doi: 10.1093/nar/gkv273. Epub 2015 Apr 6.

38.

Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer.

Attaluri A, Kandala SK, Wabler M, Zhou H, Cornejo C, Armour M, Hedayati M, Zhang Y, DeWeese TL, Herman C, Ivkov R.

Int J Hyperthermia. 2015 Jun;31(4):359-74. doi: 10.3109/02656736.2015.1005178. Epub 2015 Mar 26.

39.

In reply to Raince and Bloom and Olson.

Alcorn SR, DeWeese TL, Ellsworth S, Smith TJ.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):452-3. doi: 10.1016/j.ijrobp.2014.10.052. No abstract available.

PMID:
25636771
40.

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.

Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG.

Cancer Immunol Res. 2015 Apr;3(4):345-55. doi: 10.1158/2326-6066.CIR-14-0196. Epub 2014 Dec 19.

41.

Low interrater reliability in grading of rectal bleeding using National Cancer Institute Common Toxicity Criteria and Radiation Therapy Oncology Group Toxicity scales: a survey of radiation oncologists.

Huynh-Le MP, Zhang Z, Tran PT, DeWeese TL, Song DY.

Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1076-82. doi: 10.1016/j.ijrobp.2014.08.014. Epub 2014 Oct 13.

42.

Patterns of care among patients receiving radiation therapy for bone metastases at a large academic institution.

Ellsworth SG, Alcorn SR, Hales RK, McNutt TR, DeWeese TL, Smith TJ.

Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):1100-1105. doi: 10.1016/j.ijrobp.2014.04.028. Epub 2014 Jul 8.

43.

Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888.

Tuli R, Surmak AJ, Reyes J, Armour M, Hacker-Prietz A, Wong J, DeWeese TL, Herman JM.

Transl Oncol. 2014 May 13. pii: S1936-5233(14)00038-2. doi: 10.1016/j.tranon.2014.04.003. [Epub ahead of print]

44.

Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content.

Wabler M, Zhu W, Hedayati M, Attaluri A, Zhou H, Mihalic J, Geyh A, DeWeese TL, Ivkov R, Artemov D.

Int J Hyperthermia. 2014 May;30(3):192-200. doi: 10.3109/02656736.2014.913321.

45.

Absorbable hydrogel spacer use in men undergoing prostate cancer radiotherapy: 12 month toxicity and proctoscopy results of a prospective multicenter phase II trial.

Uhl M, Herfarth K, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, Weber DC, Miralbell R, Song DY, DeWeese TL.

Radiat Oncol. 2014 Apr 24;9:96. doi: 10.1186/1748-717X-9-96.

46.

Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate.

Regter S, Hedayati M, Zhang Y, Zhou H, Dalrymple S, Koch CJ, Isaacs JT, DeWeese TL.

Prostate. 2014 Jun;74(8):805-10. doi: 10.1002/pros.22803. Epub 2014 Mar 27.

47.

Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen.

Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE.

ChemMedChem. 2014 Jul;9(7):1356-60. doi: 10.1002/cmdc.201300549. Epub 2014 Mar 3.

48.

Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor.

Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE.

Nanomedicine (Lond). 2014 Dec;9(18):2729-43. doi: 10.2217/nnm.13.207.

49.

Irreversible inhibition of DNA polymerase β by small-molecule mimics of a DNA lesion.

Arian D, Hedayati M, Zhou H, Bilis Z, Chen K, DeWeese TL, Greenberg MM.

J Am Chem Soc. 2014 Feb 26;136(8):3176-83. doi: 10.1021/ja411733s. Epub 2014 Feb 11.

50.

Burnout in United States academic chairs of radiation oncology programs.

Kusano AS, Thomas CR Jr, Bonner JA, DeWeese TL, Formenti SC, Hahn SM, Lawrence TS, Mittal BB.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):363-8. doi: 10.1016/j.ijrobp.2013.09.027. Epub 2013 Nov 1.

PMID:
24189126

Supplemental Content

Loading ...
Support Center